NCT01482845 - A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Alzheimer's Disease

Interventions

DRUG

ABT-126

Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.

DRUG

Placebo

Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.

Trial Locations (3)

32806

Site Reference ID/Investigator# 62903, Orlando

33009

Site Reference ID/Investigator# 62904, Hallandale

91206

Site Reference ID/Investigator# 62908, Glendale